(Q28660706)

English

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

scientific article (publication date: 2014)

In more languages

Statements

scholarly article

0 references

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study (English)

0 references

0 references

multicenter clinical trial

0 references

0 references

lupus erythematosus

1 reference

based on heuristic

inferred from title

systemic lupus erythematosus

1 reference

based on heuristic

inferred from title

Caroline Gordon

11

object named as

Caroline Gordon

0 references

Michelle A. Petri

3

object named as

Michelle A Petri

0 references

4

object named as

Vibeke Strand

0 references

Kenneth C. Kalunian

2

object named as

Kenneth Kalunian

0 references

author name string

Daniel J Wallace

1

0 references

Frederic A Houssiau

5

0 references

Marilyn Pike

6

0 references

Brian Kilgallen

7

0 references

Sabine Bongardt

8

0 references

Anna Barry

9

0 references

Lexy Kelley

10

0 references

language of work or name

0 references

publication date

January 2014

0 references

Annals of the Rheumatic Diseases

0 references

73

0 references

1

0 references

183-90

0 references

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3888603

17 March 2017

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3888603

17 March 2017

Measuring outcomes in systemic lupus erythematosus clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3888603

3 June 2018

Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3888603

3 June 2018

New and emerging treatment approaches to lupus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3888603

3 June 2018

B cells as therapeutic targets in SLE.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3888603

3 June 2018

Numerical scoring for the BILAG-2004 index

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3888603

3 June 2018

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3888603

3 June 2018

Numerical scoring for the Classic BILAG index

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3888603

3 June 2018

The BILAG-2004 index is sensitive to change for assessment of SLE disease activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3888603

3 June 2018

Why can't we find a new treatment for SLE?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3888603

3 June 2018

Understanding the epidemiology and progression of systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3888603

3 June 2018

Targeting CD22 as a strategy for treating systemic autoimmune diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3888603

3 June 2018

British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3888603

3 June 2018

B-cell targeting: a novel approach to immune intervention today and tomorrow

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3888603

3 June 2018

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3888603

3 June 2018

Epratuzumab: targeting B-cell malignancies through CD22

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3888603

3 June 2018

Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3888603

3 June 2018

Systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202760

21 January 2018

Systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202760

21 January 2018

Generic versus disease-specific measures of health-related quality of life in systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1136%2FANNRHEUMDIS-2012-202760

21 January 2018

CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3888603

27 November 2018

Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls

1 reference

https://pubmed.ncbi.nlm.nih.gov/23313811

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systemic lupus erythematosus disease activity index 2000

1 reference

https://pubmed.ncbi.nlm.nih.gov/23313811

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ANNRHEUMDIS-2012-202760

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28660706&oldid=1619142876"